Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses
Artículo
Open/
Interim-analysis-IA-of-OPTIC.pdf (225.9Kb)Access note
Acceso a solo metadatos
Publication date
2020Metadata
Show full item record
Cómo citar
Cómo citar
Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses
Patrocinador
ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Indexation
Artículo de publicación ISI
Quote Item
Journal of Clinical Oncology Volumen: 38 Número: 15 Suplemento: S May 2020
Collections